Please use this identifier to cite or link to this item: https://doi.org/10.1097/JTO.0b013e318168c801
DC FieldValue
dc.titleEvidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
dc.contributor.authorWong, A.S.
dc.contributor.authorSoong, R.
dc.contributor.authorSeah, S.B.-K.
dc.contributor.authorLim, S.-W.
dc.contributor.authorChuah, K.-L.
dc.contributor.authorNga, M.-E.
dc.contributor.authorChin, T.-M.
dc.contributor.authorSoo, R.A.
dc.date.accessioned2014-11-26T07:44:35Z
dc.date.available2014-11-26T07:44:35Z
dc.date.issued2008-04
dc.identifier.citationWong, A.S., Soong, R., Seah, S.B.-K., Lim, S.-W., Chuah, K.-L., Nga, M.-E., Chin, T.-M., Soo, R.A. (2008-04). Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. Journal of Thoracic Oncology 3 (4) : 400-404. ScholarBank@NUS Repository. https://doi.org/10.1097/JTO.0b013e318168c801
dc.identifier.issn15560864
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/109333
dc.description.abstractINTRODUCTION: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are gaining an increasing role in the management of advanced non-small cell lung cancer (NSCLC). There is mounting interest in the benefit of administering a second TKI after failure of the first TKI, especially in Asian patients, in whom they are expected to be more efficacious. METHODS: We did a retrospective analysis of patients receiving both gefitinib and erlotinib in our institution during a 2-year period. Patients were to have received the second TKI after progressive disease on the first TKI. EGFR gene mutation analysis was done on patient tumor samples. RESULTS: Fourteen patients were included in the analysis, all of whom received erlotinib after progression on gefitinib. Chinese race, females, never-smokers, and adenocarcinoma subtype were predominant in their respective categories. Disease control rate was 64.3% (9 of 14) for gefitinib. Disease control rate for erlotinib administered after progression on gefitinib was 35.7% (5 of 14). All patients who achieved disease control with erlotinib after progression on gefitinib were never-smokers with adenocarcinoma subtype, who had prior disease control on gefitinib. Presence of EGFR mutations predicted for disease control with gefitinib, and for disease control with erlotinib after gefitinib failure. CONCLUSION: A significant proportion of typical gefitinib-sensitive Asian NSCLC patients can have disease control with erlotinib after gefitinib failure. The role of subsequent administration of a second EGFR TKI after failure of the first TKI in advanced NSCLC should be further pursued. © 2008International Association for the Study of Lung Cancer.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1097/JTO.0b013e318168c801
dc.sourceScopus
dc.subjectAsian
dc.subjectErlotinib
dc.subjectGefitinib
dc.subjectNon-small cell lung cancer
dc.typeArticle
dc.contributor.departmentPHARMACY
dc.contributor.departmentNATIONAL UNIVERSITY MEDICAL INSTITUTES
dc.description.doi10.1097/JTO.0b013e318168c801
dc.description.sourcetitleJournal of Thoracic Oncology
dc.description.volume3
dc.description.issue4
dc.description.page400-404
dc.identifier.isiut000255209000013
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

56
checked on Nov 6, 2019

WEB OF SCIENCETM
Citations

45
checked on Nov 6, 2019

Page view(s)

63
checked on Nov 9, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.